Small Cell Lung Cancer: What is the Role of IO Therapy in the Frontline Setting?

EP: 1.Current Strategies in Diagnosis and Classification of Small Cell Lung Cancer

EP: 2.Small Cell Lung Cancer: What is the Role of Biomarker Testing?

EP: 3.Real-World Data and Observed AEs With Frontline Chemo IO Therapy in SCLC

EP: 4.Novel and Emerging Frontline Treatment Strategies in SCLC

EP: 5.Overview of Frontline Treatment Options in Small Cell Lung Cancer

Now Viewing

EP: 6.Small Cell Lung Cancer: What is the Role of IO Therapy in the Frontline Setting?

EP: 7.Overview of Second-Line Treatment Options in SCLC

EP: 8.Clinical Data With Lurbinectedin in Small Cell Lung Cancer

EP: 9.The Evolving Treatment Landscape of Small Cell Lung Cancer

Transcript:

Christian Grohé, MD:What do you think is the role of immunotherapy in the first-line setting? Is that used most in extensive or mostly use of limited-stage disease?

Laurent Greiller, MD:We can say that extensive-stage small cell lung cancer patient immunotherapy is a standard combination with chemotherapy platinum receptor. We have the data from the CASPIAN trial ((NCT03043872), and from the IMPOWER133 trial (NCT02763579). For patients with limited-stage small cell lung cancer, IO is not a standard because the STIMULI trial (NCT02046733) assessed the role of maintenance therapy after chemoradiotherapy in patients with limited-stage small cell lung cancer. The IO tested in this trial was a combination of [nivolumab ipilimumab] and this randomized phase 2 trial was negative. Today, there are a number of ongoing trials assessing the addition of immunotherapy to the standard radiochemotherapy. The results of these trials are still pending. So, for limited-stage small cell lung cancer, IO is not a standard at least today.

Transcript edited for clarity.